会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Gaming headset vibrator
    • 游戏耳机振动器
    • US08290192B2
    • 2012-10-16
    • US11050140
    • 2005-02-03
    • John Patrick WongJeff Crampton
    • John Patrick WongJeff Crampton
    • A61F11/06H04R1/10H04R25/00A63F9/24
    • H04R1/1091H04R1/26H04R5/033H04R2460/13
    • A vibrating headset capable of generating a vibration of variable operational characteristics in the earpiece of the vibrating headset is disclosed. The vibrating headset may include one or more earpieces, each of which includes a speaker and a vibrator mechanism, wherein the vibrator mechanism receives a vibration input signal which is distinct from the audio input signal received by the speaker and defines the variable operational characteristics of the vibration to be generated by the vibrator mechanism. A gaming apparatus including a gaming device and a vibrating headset communicably coupled to the gaming device for generating vibrations of variable operational characteristics in response to receiving a vibration input signal from the gaming device is also provided. Finally, a method of creating vibrations defined by at least one variable operational characteristic in an earpiece of a vibrating headset is provided.
    • 公开了能够在振动式耳机的耳机中产生可变操作特性的振动的振动式耳机。 振动式耳机可以包括一个或多个听筒,每个听筒包括扬声器和振动器机构,其中振动器机构接收与扬声器接收的音频输入信号不同的振动输入信号,并且定义可变操作特性 由振动器机构产生的振动。 还提供了一种包括游戏装置和可触发地耦合到游戏装置的振动式耳机的游戏装置,用于响应于接收来自游戏装置的振动输入信号而产生可变操作特性的振动。 最后,提供了一种创建由振动式耳机的耳机中的至少一个可变操作特性定义的振动的方法。
    • 3. 发明申请
    • Dosage Form for Time-Varying Patterns of Drug Delivery
    • 药物递送时间变化模式的剂型
    • US20070207204A1
    • 2007-09-06
    • US11744999
    • 2007-05-07
    • David EdgrenPatrick WongShu Li
    • David EdgrenPatrick WongShu Li
    • A61K9/66
    • A61K9/0004A61K31/277
    • The present invention provides a multi-release oral drug delivery system that initiates drug release following an initial drug-free release interval, after administration to a subject, and a second drug-free release period before release of another dose of drug. The system has (1) inner compartments enclosed within a semipermeable membrane, and (2) a drug coating on the exterior of the semipermeable membrane surrounded by a microporous membrane, which microporous membrane is permeable to fluid and drug. The drug coating is released after the initial drug-free release interval. An inner compartment drug is released after a second drug-free release interval provided by a drug-free inner compartment.
    • 本发明提供一种多次释放的口服药物递送系统,其在给予受试者之后,在初始无药物释放间隔之后启动药物释放,以及释放另一剂量药物之前的第二无药物释放期。 该系统具有(1)封闭在半透膜内的内隔室,(2)由微孔膜包围的半透膜外部的药物涂层,该微孔膜可渗透流体和药物。 药物涂层在初始无药物释放间隔后释放。 在由无药物的内隔室提供的第二无药物释放间隔后释放内室药物。
    • 4. 发明申请
    • Volume Efficient Controlled Release Dosage Form
    • 体积有效的控制释放剂型
    • US20070184112A1
    • 2007-08-09
    • US11684821
    • 2007-03-12
    • Patrick WongFrancisco JaoDavid EdgrenRobert SkluzacekShu Li
    • Patrick WongFrancisco JaoDavid EdgrenRobert SkluzacekShu Li
    • A61K9/24
    • A61K9/0004
    • A dosage form that facilitates the controlled release of an active agent at a desired release rate or release rate profile includes a bi-layer membrane system and an osmotic core. The bi-layer membrane system includes a semipermeable membrane and an osmosensitive membrane and forms an internal compartment occupied by the osmotic core. The osmotic core includes an active agent composition and a light push layer. A passageway is formed through the bi-layer membrane system and permits expulsion of the active agent composition from the dosage form during operation. The bi-layer membrane system and the osmotic core are formulated and formed to provide controlled release of the active agent included in the active agent composition, while simultaneously facilitating increased loading of active agent within a dosage form of given dimension and increasing the delivery efficiency of such active agent relative to prior osmotic dosage forms including a push layer.
    • 有利于以期望的释放速率或释放速率曲线控制释放活性剂的剂型包括双层膜系统和渗透核。 双层膜系统包括半透膜和渗透膜,并形成由渗透芯占据的内部隔室。 渗透芯包括活性剂组合物和轻推层。 通过双层膜系统形成通道,并允许活性剂组合物在操作期间从剂型中排出。 双层膜系统和渗透芯被配制和形成以提供包含在活性剂组合物中的活性剂的受控释放,同时促进活性剂在给定维度的剂型中的负载增加,并且提高 这种活性剂相对于包括推层的先前的渗透剂型。
    • 8. 发明申请
    • Dosage forms and layered deposition processes for fabricating dosage forms
    • 用于制备剂型的剂量形式和分层沉积方法
    • US20050118246A1
    • 2005-06-02
    • US10976589
    • 2004-10-29
    • Patrick WongB. Silber
    • Patrick WongB. Silber
    • A61K9/00A61K9/70A61K9/14
    • A61K9/0065A61F2013/0296A61K9/703A61K9/7084A61K9/7092
    • Disclosed are transdermal or transmucosal dosage forms which include a matrix and a drug where the total amount of drug present in the dosage form exceeds the solubility limit of the drug in the matrix. Also disclosed are transdermal or transmucosal dosage forms which include two or more drug-containing layers and one or more intervening hydrophilic layers where the two or more drug-containing layers being separated from one another by the one or more intervening hydrophilic layers. Methods for delaying release and delivery of an active from an active layer disposed in a transdermal or transmucosal dosage form are also disclosed, as well as methods for manufacturing transdermal or transmucosal dosage forms by providing a substrate and disposing at least one transdermal or transmucosal dosage form layer on the substrate using a printing process.
    • 公开了透皮或透粘膜剂型,其包括基质和药物,其中存在于剂型中的药物的总量超过药物在基质中的溶解度极限。 还公开了透皮或透粘膜剂型,其包括两个或更多个药物含有层和一个或多个中间亲水层,其中两个或更多个药物含有层通过一个或多个中间亲水层彼此分离。 还公开了延缓活性物质从透皮或经粘膜剂型形成的活性层的释放和递送的方法,以及通过提供底物和设置至少一种透皮或透粘膜剂型形成透皮或经粘膜剂型的方法 使用印刷方法在基板上。